vs
Amneal Pharmaceuticals, Inc.（AMRX）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
SCANSOURCE, INC.的季度营收约是Amneal Pharmaceuticals, Inc.的1.1倍（$766.5M vs $722.5M），Amneal Pharmaceuticals, Inc.净利率更高（10.8% vs 2.2%，领先8.6%），Amneal Pharmaceuticals, Inc.同比增速更快（3.9% vs 2.5%），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（1.5% vs 0.9%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
AMRX vs SCSC — 直观对比
营收规模更大
SCSC
是对方的1.1倍
$722.5M
营收增速更快
AMRX
高出1.4%
2.5%
净利率更高
AMRX
高出8.6%
2.2%
两年增速更快
AMRX
近两年复合增速
0.9%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $766.5M |
| 净利润 | $78.0M | $16.5M |
| 毛利率 | 44.3% | 13.4% |
| 营业利润率 | 19.6% | 2.3% |
| 净利率 | 10.8% | 2.2% |
| 营收同比 | 3.9% | 2.5% |
| 净利润同比 | 410.5% | -3.3% |
| 每股收益（稀释后） | $0.19 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXSCSC
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $766.5M | ||
| Q3 25 | $784.5M | $739.6M | ||
| Q2 25 | $724.5M | $812.9M | ||
| Q1 25 | $695.4M | $704.8M | ||
| Q4 24 | $730.5M | $747.5M | ||
| Q3 24 | $702.5M | $775.6M | ||
| Q2 24 | $701.8M | $746.1M |
净利润AMRXSCSC
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $16.5M | ||
| Q3 25 | $2.4M | $19.9M | ||
| Q2 25 | $22.4M | $20.1M | ||
| Q1 25 | $12.2M | $17.4M | ||
| Q4 24 | $-31.1M | $17.1M | ||
| Q3 24 | $-156.0K | $17.0M | ||
| Q2 24 | $6.0M | $16.1M |
毛利率AMRXSCSC
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 13.4% | ||
| Q3 25 | 34.9% | 14.5% | ||
| Q2 25 | 39.5% | 12.9% | ||
| Q1 25 | 36.8% | 14.2% | ||
| Q4 24 | 36.0% | 13.6% | ||
| Q3 24 | 38.4% | 13.1% | ||
| Q2 24 | 35.6% | 13.0% |
营业利润率AMRXSCSC
| Q1 26 | 19.6% | — | ||
| Q4 25 | 13.8% | 2.3% | ||
| Q3 25 | 9.0% | 3.5% | ||
| Q2 25 | 15.4% | 3.3% | ||
| Q1 25 | 14.4% | 3.2% | ||
| Q4 24 | 10.4% | 2.5% | ||
| Q3 24 | 12.6% | 2.3% | ||
| Q2 24 | 13.6% | 2.9% |
净利率AMRXSCSC
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | 2.2% | ||
| Q3 25 | 0.3% | 2.7% | ||
| Q2 25 | 3.1% | 2.5% | ||
| Q1 25 | 1.8% | 2.5% | ||
| Q4 24 | -4.3% | 2.3% | ||
| Q3 24 | -0.0% | 2.2% | ||
| Q2 24 | 0.9% | 2.2% |
每股收益（稀释后）AMRXSCSC
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $0.75 | ||
| Q3 25 | $0.01 | $0.89 | ||
| Q2 25 | $0.07 | $0.87 | ||
| Q1 25 | $0.04 | $0.74 | ||
| Q4 24 | $-0.10 | $0.70 | ||
| Q3 24 | $0.00 | $0.69 | ||
| Q2 24 | $0.02 | $0.66 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $197.7M | $83.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $910.9M |
| 总资产 | $3.5B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXSCSC
| Q1 26 | $197.7M | — | ||
| Q4 25 | $282.0M | $83.5M | ||
| Q3 25 | $201.2M | $124.9M | ||
| Q2 25 | $71.5M | $126.2M | ||
| Q1 25 | $59.2M | $146.3M | ||
| Q4 24 | $110.6M | $110.5M | ||
| Q3 24 | $74.0M | $145.0M | ||
| Q2 24 | $43.8M | $185.5M |
总债务AMRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
股东权益AMRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $910.9M | ||
| Q3 25 | $-109.5M | $914.0M | ||
| Q2 25 | $-112.1M | $906.4M | ||
| Q1 25 | $-131.7M | $901.7M | ||
| Q4 24 | $-109.3M | $900.7M | ||
| Q3 24 | $-93.4M | $920.9M | ||
| Q2 24 | $-57.5M | $924.3M |
总资产AMRXSCSC
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.7B | $1.7B | ||
| Q3 25 | $3.6B | $1.7B | ||
| Q2 25 | $3.4B | $1.8B | ||
| Q1 25 | $3.4B | $1.7B | ||
| Q4 24 | $3.5B | $1.7B | ||
| Q3 24 | $3.5B | $1.8B | ||
| Q2 24 | $3.5B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $30.8M |
| 自由现金流经营现金流 - 资本支出 | — | $28.9M |
| 自由现金流率自由现金流/营收 | — | 3.8% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.87× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $30.8M | ||
| Q3 25 | $118.5M | $23.2M | ||
| Q2 25 | $83.8M | — | ||
| Q1 25 | $7.4M | $66.1M | ||
| Q4 24 | $118.1M | $-6.2M | ||
| Q3 24 | $141.8M | $44.8M | ||
| Q2 24 | $39.7M | — |
自由现金流AMRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | $28.9M | ||
| Q3 25 | $106.2M | $20.8M | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | $64.6M | ||
| Q4 24 | $102.9M | $-8.2M | ||
| Q3 24 | $124.8M | $42.5M | ||
| Q2 24 | $29.0M | — |
自由现金流率AMRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | 3.8% | ||
| Q3 25 | 13.5% | 2.8% | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | 9.2% | ||
| Q4 24 | 14.1% | -1.1% | ||
| Q3 24 | 17.8% | 5.5% | ||
| Q2 24 | 4.1% | — |
资本支出强度AMRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 0.3% | ||
| Q3 25 | 1.6% | 0.3% | ||
| Q2 25 | 3.2% | 0.3% | ||
| Q1 25 | 1.9% | 0.2% | ||
| Q4 24 | 2.1% | 0.3% | ||
| Q3 24 | 2.4% | 0.3% | ||
| Q2 24 | 1.5% | 0.2% |
现金转化率AMRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 1.87× | ||
| Q3 25 | 50.00× | 1.17× | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | 6.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
暂无分部数据
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
